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Abstract 
Review on Birt-Hogg-Dubé syndrome (BHDS), 
with data on clinics, and the genes implicated. 
Identity 
Other names 
Hornstein-Knickenberg Syndrome 
Fibrofolliculomas with Trichodiscomas and 
Acrochordons 
Note 
Birt-Hogg-Dubé syndrome (BHDS) is characterized 
by renal oncocytic tumors, benign skin tumors 
(fibrofolliculomas and trichodiscomas), and 
spontaneous pneumothorax. The first description of 
an affected family was provided by Birt, Hogg, and 
Dubé in 1977. 
Inheritance 
Autosomal Dominant with intrafamilial and 
interfamilial phenotypic variability. Prevalence is 
estimated at about 1/200000 although the condition 
is probably under-diagnosed because of the wide 
phenotypic variability. 
Clinics 
Phenotype and clinics 
BHDS is a genodermatosis characterized by the 
triad of benign tumors of the hair follicle,  
spontaneous pneumothorax and kidney tumors. 
These manifestations do not have to be 
simultaneously present in the same individual in 
order to establish a diagnosis of BHDS, since the 
phenotype is variable and penetrance is not 
complete. Other manifestations, such as parotid 
oncocytomas, parathyroid adenomas, neural tissue 
tumors, lipomas, angiolipomas, colorectal 
adenomas, and connective tissue abnormalities, 
have been occasionally observed but their 
association with the syndrome is not yet proven. 
Cutaneous tumors are fibrofolliculomas, 
trichodiscomas and/or acrochordons. 
Fibrofolliculomas and trichodiscomas tend to 
appear in the third or fourth decade of life as small 
white or skin-colored multiple papules on the face, 
neck and upper trunk. Acrochordon is a non 
specific designation for small and soft skin tags. 
Almost all BHDS patients have lung cysts (80%-
100%), and one-fifth develop spontaneous 
pneumothorax. Typically there are multiple, 
irregularly-shaped, thin-walled pulmonary cysts of 
various sizes, predominantly distributed in the 
lower medial and subpleural regions of the lung. 
Pathological characteristics indicate that the BHDS 
lung cyst is a hamartoma-like lesion associated with 
deranged mTOR signaling. 
The presence of spontaneous pneumothorax in a 
member of a BHDS family could be used as a 
criterion for the diagnosis of BHDS due to its 
strong association with BHDS. 
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Multiple trichodiscomas of the neck. 
 
 
Differential Diagnosis 
BHDS manifestations occur in other diseases. 
These include renal cancer syndromes, namely von 
Hippel-Lindau disease, hereditary 
leiomyomatosis/renal cell cancer, hereditary 
papillary renal cancer, hereditary clear cell renal 
cell cancer, tuberous sclerosis complex, familial 
paraganglioma syndrome, and familial oncocytoma. 
Tuberous sclerosis, Cowden syndrome and Brooke-
Spiegler syndrome are characterized by cutaneous 
manifestations that can present similaraties with 
BHDS lesions. However, the cutaneous 
hamartomas in these conditions are angiofibromas, 
trichilemmomas and trichoepitheliomas, 
respectively. 
BHDS should also be differentiated from 
syndromes associated with cystic lung disease and 
pneumothorax. Lymphangioleiomyomatosis and 
pulmonary endometriosis should be considered in 
women of reproductive age. 
Neoplastic risk 
Approximately 27% of BHDS patients develop 
renal tumors of different histological type: 
- chromophobe (34%), 
- hybrid chromophobe/oncocytic (50%), 
- oncocytoma (5%), and 
- clear cell renal carcinoma (9%). 
Hybrid tumors are most characteristic of this 
condition, and several lesions initially diagnosed as 
oncocytomas or chromofobe tumors have been 
defined as hybrid tumors upon reappraisal. Multiple 
histological types of kidney tumors can be found in 
the same BHDS family, in the same patient or even 
in the same kidney. 
BHDS patients with bilateral renal masses and 
oncocytoma/oncocytic neoplasm on one side have  
significantly lower histological concordance rates in 
the contralateral kidney compared to non-BHDS 
patients; this underscores the need for careful 
periodic surveillance, to detect lesions with a higher 
malignant potential. 
Treatment 
- No specific medical treatment exists for the 
cutaneous lesions of BHDS. Surgical removal has 
provided definitive treatment of solitary 
perifollicular fibromas and electrodesiccation may 
be helpful in removal of multiple lesions, which, 
however, can recur. 
- High-resolution CT scan should be performed to 
identify lung cysts. Patients should be educated 
about the risk of pneumothorax. 
- Individuals at risk or affected by BHDS should be 
radiographically screened for renal tumors at 
periodic intervals and they are best treated with 
nephron sparing surgical approaches. 
- Colonoscopy should be considered, although there 
is as yet no evidence that the risk of colorectal 
tumors is increased in BHDS. 
FLCN loss has been shown to result in upregulation 
of the AKT-mTOR pathway both in vitro and in a 
conditional Flcn mouse knockout model.  
These results suggest that mTOR inhibitors such as 
rapamycin analogues (i.e. sirolimus) might be 
useful potential therapeutic agents for BHDS-
associated renal tumors. 
Prognosis 
Prognosis depends on the number, type and age at 
diagnosis of kidney tumors.  
Hybrid and chromophobe tumors have malignant 
potential, while pure renal oncocytomas are benign. 
Mean age at diagnosis of kidney tumors is 50.7 
years. 
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Genes involved and 
proteins 
FLCN 
Location 
17p11.2 
Note 
Genomic coordinates (GRCh37): 17: 17115522 - 
17140501. 
DNA/RNA 
Description 
Total gene size: 24971 bp. 
Transcription 
Alternative splicing results in two transcript 
variants encoding different isoforms. mRNA is 
expressed in a variety of tissues, including the skin, 
the kidney, the lung, the pancreas, parotid gland, 
and the brain. Tissues with reduced expression of 
FLCN mRNA include heart, muscle and liver. 
FLCN mRNA is not expressed in renal tumors from 
BHDS patients. 
Protein 
Note 
Folliculin 
Description 
The protein contains a conserved SLS potential 
phosphorylation site, a glutamic acid-rich coiled-
coil domain, an N-glycosylation site, and 3 
myristoylation sites. 
Function 
FLCN function is not yet completely understood. It 
binds to FNIP1 and FNIP2 (via its C-terminus) and 
colocalizes with them in the cytoplasm. However, 
unbound FLCN is mainly localized in the nucleus. 
FLCN-FNP1 and FLCN-FNP2 complexes interact 
with AMPK and seem to modulate mTOR activity 
with opposite effects in a context-dependent 
manner. FLCN is phosphorylated by AMPK and 
mTOR, and phosphorylation is enhanced by 
binding with FNIP1 and FNIP2. 
FLCN has also a role in the regulation of key TGF-
beta signalling. Its inactivation leads to activation 
of the transcription factor TFE3 and to 
overexpression of nuclear genes involved in the 
transcription and replication of the mitochondrial 
genome. 
Structure: The crystal structure of folliculin 
carboxy-terminal domain suggests that it is 
distantly related to Differentially Expressed in 
Normal cells and Neoplasia (DENN) domain 
proteins, that serve as guanine exchange factors 
(GEFs) for Rab GTPases.  
In particular, folliculin displays GEF activity 
towards Rab35, facilitating its role in vesicle 
membrane transport. 
Mutations 
Note 
Frameshift insertions or deletions within a 
mononucleotide repeat tract containing 8 cytosines 
within exon 11 are the most frequent FLCN 
constitutional mutations, detected in approximately 
50% of BHDS families. The spectrum of additional 
mutations is heterogeneous. Overall, FLCN point 
mutations are found in 60%-88% of BHDS cases, 
depending on selection criteria. Large FLCN 
intragenic deletions and duplications may account 
for approximately 5% of BHDS cases. The tract 
including the 5' UTR and exon 1 seems to be a hot-
spot for large deletions. 
Animal Models: Hereditary multifocal renal 
cystadenocarcinoma and nodular dermatofibrosis is 
a naturally occurring canine kidney cancer 
syndrome that was originally described in German 
shepherd dogs, and is caused by canine Bhd gene 
mutations. 
In a colony of Sprague-Dawley rats in Japan, 
designated the 'Nihon' rat, a germline frameshift 
mutation in the Bhd gene resulting in a premature 
stop codon was found to be associated with 
hereditary renal carcinoma. The homozygous 
mutant condition was lethal at an early stage of 
foetal life in the rat. 
Other rat or mouse BHDS models were generated 
deleting FLCN homologues: targeted homozygous 
deletion of Bhd in rat and mice was embryonic 
lethal whereas heterozygous animals manifested 
hyperproliferative diseases of various organs 
including preneoplastic kidney lesions and kidney 
tumors. 
Deletion of the FLCN homologue in Drosophila 
causes growth delay. In this model, growth can be 
rescued by dietary changes, suggesting that 
modulation of the local nutrient conditions might be 
a potential treatment for BHDS lesions. 
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